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Objective. To investigate the relationship between intestinal inflammation and the central and peripheral innate immune system in the pathogenesis of HLA-B27-associated spondyloarthritis using an HLA-B27-transgenic (B27-Tg) rat model.
Methods. The myeloid compartment of the blood and bone marrow (BM) of B27-Tg rats, as well as HLA-B7-Tg and non-Tg rats as controls, was evaluated by flow cytometry. Plasma from rats was assessed by enzymelinked immunosorbent assay for levels of CCL2 and interleukin-1a (IL-1a). Rats were treated with antibiotics for 4 weeks, and the myeloid compartment of the blood and BM was evaluated by flow cytometry. The osteoclastogenic potential of BM-derived cells from antibiotictreated rats, in the presence or absence of tumor necrosis factor (TNF), was evaluated in vitro.
Results. B27-Tg rats had substantially higher numbers of circulating Lin2CD172a1CD43 low monocytes as compared to control animals, and this was significantly correlated with higher levels of plasma CCL2. Antibiotic treatment of B27-Tg rats markedly reduced the severity of ileitis, plasma levels of CCL2 and IL-1a, and number of BM and blood Lin2CD172a1CD43 low monocytes, a cell subset shown in the present study to have the greatest in vitro osteoclastogenic potential. Antibiotic treatment also prevented the TNF-dependent enhancement of osteoclastogenesis in B27-Tg rats.
Conclusion. Microbiota-dependent intestinal inflammation in B27-Tg rats directly drives the systemic inflammatory and bone-erosive potential of the monocyte compartment.
The HLA-B27 allele of major histocompatibility complex (MHC) class I is a major risk factor for the development of human spondyloarthritis (SpA). However, its exact contribution to disease enhancement is poorly understood. Transgenic (Tg) rats that express the human HLA-B27 and b 2 -microglobulin genes (B27-Tg rats) develop multisystem inflammation that resembles the SpA clinical spectrum in humans (1, 2) . Inflammation in B27-Tg rats starts in the intestine, with ileitis occurring before 10 weeks of age, followed by arthritis, psoriasis, and nail dystrophy (2) . A link between gut pathology and peripheral symptoms has been known for decades, as indicated by the fact that animals raised in germ-free conditions develop neither colitis nor arthritis (3) .
There has been renewed interest in the intestinal environment and its contribution to the development of B27-associated disease. It is now evident that the intestinal microbiome in B27-Tg rats is profoundly different from that of healthy animals (4) . Importantly, the development of gut pathology in B27-Tg rats is associated with specific strains of commensal bacteria (i.e., Bacteroides vulgatus), which can be manipulated with oral antibiotic treatment (5, 6) . The impact of microbial dysbiosis on the central and systemic immune system, and the subsequent effect of this on disease development, is currently under investigation. Recent work in mice has shown that acute Toxoplasma gondii-driven intestinal inflammation can trigger changes in the bone marrow (BM) compartment, specifically BMderived monocyte precursor cells, wherein the function of these cells is fundamentally altered once they migrate into infected mucosal tissue (7) .
Interestingly, B27-Tg animals lack MHC class IIpositive CD1031CD172a low migrating dendritic cells, which are involved in controlling intestinal immune responses (8) . Furthermore, osteoclast precursors in B27-Tg rats, compared to those in control animals, have enhanced differentiation in response to tumor necrosis factor (TNF), which contributes to the occurrence of B27-associated bone loss (9) . It still remains to be determined, however, how changes in the myeloid compartment and B27-associated microbial dysbiosis could affect the central and peripheral myeloid compartments, and how these processes might alter the maturation of these cells into osteoclasts. Herein, we have characterized monocyte populations in B27-Tg rats and investigated the effects of oral antibiotics on both intestinal pathology and the myeloid compartment. The results reveal close correlations between gut pathology and the distribution of monocytes in B27-Tg rats, and show that these alterations could directly contribute to B27-associated bone loss.
MATERIALS AND METHODS
Animal studies. Heterozygous B27-Tg rats, as well as HLA-B7-Tg PVG rats as controls, were bred in accordance with previously described license provisions (8) . All animals were maintained under specific pathogen-free conditions at the University of Glasgow, and used under licenses issued by the UK Home Office. All rats were used between 10 weeks and 18 weeks of age.
In vivo antibiotic treatment. In the active treatment group, 10-14-week-old rats were given 50 mg/kg/day of vancomycin and 2.5 mg/kg/day of ampicillin/metranidazole/neomycin resuspended in filtered sterile drinking water. Administration of antibiotics was performed by gavage daily on all week days for 4 consecutive weeks. For the untreated control group, an equal volume of sterile drinking water was given. Samples of blood were obtained twice per week from the tail vein, and plasma was stored. On day 26, animals were culled and the blood, hind limbs, and gut were harvested for downstream analysis.
Flow cytometry. The white cell fraction of freshly isolated rat BM and blood was obtained by lysis of red cells using ACK lysing buffer (Life Technologies), followed by staining with fluorochrome-labeled antibodies and/or with biotinylated antibodies and fluorochrome-labeled streptavidin. Briefly, Fcg receptor was blocked using purified mouse anti-rat CD32 (D34-485; BD Biosciences). The cells were then stained with biotinylated mouse anti-rat Igk, CD90 (OX-6), CD45RA (OX-33), and Brilliant Violet 650-streptavidin (BioLegend). Monocytes were identified using phycoerythrin-conjugated CD172a (OX-41; BioLegend), allophycocyanin-conjugated CD43 (W3/13; BioLegend), and V450 or fluorescein isothiocyanate-conjugated CD11b (WT.5; BD Biosciences). A DAPI solution (SigmaAldrich) was used for live/dead cell exclusion. Cells were acquired using an LSRII flow cytometer (BD Biosciences), and the data were analyzed using FlowJo software (Tree Star).
Flow cytometry sorting of BM cells (BMCs). Fluorescence-labeled cells were acquired and sorted using an Aria I sorter and a 70-mm nozzle (BD Biosciences). Cells were sorted into tubes containing complete a-minimum essential medium (a-MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 0.02 mM L-glutamine, 10 units/ml penicillin, and 0.1 mg/ml streptomycin (Invitrogen Thermo Fisher Scientific), and kept at 48C until sorting was complete. Analysis of cell sorting showed a cell purity of $96%. Sorted cells were seeded in 96-well plates at 1 3 10 6 cells/ml and then incubated overnight with 50 ng/ml macrophage colony-stimulating factor (M-CSF; PeproTech). On day 1, cells were stimulated with 50 ng/ ml RANKL (PeproTech). The medium was refreshed on day 4, and on day 6 or day 7, the cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP) in accordance with the manufacturer's instructions (Acid Phosphatase TRAP kit; Sigma-Aldrich). Four representative images were acquired for each well at 10 3 magnification, using an EVOS FL Auto Cell Imaging System (Life Technologies). Osteoclasts were identified as TRAP1 cells (multinucleated cells [$3 nuclei] with purple staining), which were counted using Fiji software (ImageJ).
Measurement of fluorescent CCL2 uptake. The uptake of fluorescent CCL2 toward the CCR2 receptor was measured using site-specific AF647-labeled chemokines (purchased from the ALMAC Group), as previously described (10) . Briefly, fresh primary cells were incubated at 378C for 1 hour with 25 nM CCL2
AF647
. Cells were then washed and stained for analysis of surface marker expression by flow cytometry.
Chemotaxis assay. BM samples were collected from age-matched B27-Tg rats and B7-Tg control rats. BMCs were suspended at 5 3 10 6 cells/ml in chemotaxis buffer (Dulbecco's modified essential medium supplemented with 0.5% heat-inactivated bovine serum albumin; Life Technologies Thermo Fisher Scientific), and 100 ml of the cell suspension was placed on the top section of a bare-filter Transwell (6.5 mm in diameter) with a 5-mm pore size (Corning). Rat CCL2 (concentrations of 0, 10, 100, and 1,000 ng/ml) was added as a chemoattractant in the bottom section of the Transwells (PeproTech). After 3 hours of incubation at 378C, transmigration was assessed by counting the cells that had migrated into the bottom section of the well. Transmigrated cells were further collected and stained for flow cytometry analysis.
Enzyme-linked immunosorbent assay (ELISA). Blood was collected in heparinized tubes and plasma was stored. Levels of rat CCL2 and interleukin-1a (IL-1a) were measured by ELISA in accordance with the manufacturers' instructions (BioLegend and Thermo Fisher Scientific, respectively).
Collection of rat BMCs and quantification of osteoclastogenesis. Briefly, BM was flushed from the long bones of rats, and red cells were lysed with ACK lysing buffer. BMCs were cultured at 1 3 10 6 cells/ml in a-MEM supplemented with 10% heat-inactivated FBS, 0.02 mM L-glutamine, 10 units/ml penicillin, and 0.1 mg/ml streptomycin (Invitrogen Thermo Fisher Scientific) in the presence of 2.5 mM bglycerophosphate and 0.05 mg/ml L-ascorbic acid (SigmaAldrich) for 2 days. After incubation, nonadherent BMCs were collected, seeded at 2 3 10 5 cells/well in 96-well plates, and cultured in triplicate in the presence of 50 ng/ml M-CSF, 10 ng/ml RANKL, and 50 ng/ml TNF (PeproTech). The medium was refreshed on day 4, and on day 5, the cells were fixed and stained for TRAP. The TRAP1 cells (osteoclasts) were quantified in the same manner as described above.
Tissue processing and hematoxylin and eosin (H&E) staining for analysis of the rat ileum. Several pieces of the ileum were collected from rats under terminal anesthesia (4 atm isoflurane and 4 atm O 2 ). The ileal samples were fixed in 4% neutral buffered formalin. Samples were dehydrated via increasing concentrations of ethanol and embedded in paraffin wax blocks. Transversal sections and cross-sections of the tissue were cut at 5 mm using a microtome and stained with H&E, and then mounted with DPX mountant (Sigma-Aldrich). Stained sections were 1808 ANSALONE ET AL imaged using an EVOS FL Auto Cell Imaging System (Life Technologies) with a 10 3 objective. Villi and crypt length were measured using Fiji software. Statistical analysis. Prism version 6 (GraphPad) was used to perform all statistical analyses. P values less than or equal to 0.05 were considered significant.
RESULTS
Altered myeloid compartment characterized by increased numbers of CD43 low monocytes in B27-Tg rats. Rat monocytes within the blood and BM (11, 12) were identified as Lin2(Igk2CD90 2OX-332)SSC Figures 1A and B) . This change corresponded to a substantially higher number of circulating CD43 low monocytes in B27-Tg animals ( Figure 1C) . Interestingly, the numbers of CD43 high monocytes were not significantly altered in B27-Tg rats ( Figure 1C ).
This increased representation of CD43 low monocytes was also observed within the BM of B27-Tg rats when compared to WT and B7-Tg control rats ( Figures  1D-F) . Importantly, no differences between WT rats and B7-Tg control rats were evident in either the blood or BM ( Figures 1B, C, E, and F) .
Effects of antibiotic treatment in reducing the numbers of circulating CD43 low monocytes via restoration of plasma CCL2 levels and reduction in the number of precursor cells in the BM. Oral antibiotics are effective at attenuating signs of ileitis in B27-Tg rats (6) . Using a broad-spectrum antibiotic treatment, we ameliorated the B27-associated gut inflammation in B27-Tg rats, as indicated by reductions in the severity of ileitis after 4 weeks of oral antibiotic administration (Figures 2A and B) . Surprisingly, this treatment was associated with a reduction in the number of CD43 low monocytes not only within the bloodstream but also within the BM of B27-Tg rats (Figures 2C- low monocytes in the blood and bone marrow (BM) of HLA-B27-transgenic (B27-Tg) rats. The white cell fraction was collected from the blood and BM of wild-type (WT), B7-Tg, and B27-Tg rats and analyzed by flow cytometry. A, Representative density plots show the expression of CD11b and CD43 in circulating blood monocytes (M O s; Lin2SSC low CD172a1) from WT and B27-Tg animals. Numbers were calculated from 3 different experiments pooled together (n 5 6 rats per group). B and C, Percentages (B) and absolute numbers (C) of CD43 low and CD43 high monocytes were determined in WT, B7-Tg, and B27-Tg rats. D-F, Samples of BM were collected from WT, B7-Tg, and B27-Tg rats and analyzed for the expression of CD172a and CD43. Representative density plots show the distribution of BM monocytes in WT and B27-Tg rats (D). Percentages (E) and absolute numbers (F) of CD43 low and CD43 high monocytes were determined in the BM of WT, B7-Tg, and B27-Tg animals. Numbers were calculated from 3 different experiments pooled together (n 5 5 WT, n 5 6 B7-Tg, and n 5 6 B27-Tg). In B, C, E, and F, symbols represent individual rats; horizontal bars indicate the mean. Data were analyzed using two-way analysis of variance with Tukey's multiple comparison test. * 5 P , 0.05; ** 5 P # 0.005; *** 5 P # 0.001; **** 5 P # 0.0001. F). The antibiotic-induced modulation of monocyte composition did not occur in control animals, since we observed that treated and untreated non-Tg animals had comparable numbers of monocytes.
Rat CD43 low monocytes express CCR2 (11), which is a key chemokine receptor involved in monocyte migration from the BM into the bloodstream and recruitment of monocytes into inflamed tissues. We confirmed the expression of CCR2 in CD43 low monocytes using fluorescence-labeled CCL2 ( Figure 3A) , and also observed migration of these cells toward CCL2 ( Figure 3B ). In addition, we observed significantly higher plasma CCL2 levels in B27-Tg rats as compared to controls ( Figure 3C ).
These data indicate that there may be CCL2-dependent altered migration/recruitment of monocytes in B27-associated diseases. This possibility was supported by Figure 2 . Reduced severity of ileitis and reestablishment of normal levels of CD43 low monocytes following antibiotic (ABX) treatment of B27-Tg animals. WT and B27-Tg rats received 4 weeks of ABX, or water as a vehicle control (CTRL), and on day 26, the blood white cell fraction and BM cells were collected and stained for flow cytometry. A, Representative hematoxylin and eosin-stained sections of the ileum of ABX-and control-treated WT or B27-Tg rats are shown. Tissue sections of the ileum were visualized and digital images were captured using an EVOS FL Auto Cell Imaging System with a 10 3 objective. B, The villus-to-crypt ratio was quantified in control-and ABX-treated WT and B27-Tg rats. For each sample, the average of the length of the villus and crypt was calculated on 2 different tissue sections. Results are the mean 6 SD (n 5 3-4 ABX-treated rats and n 5 2-3 control-treated rats). C, Representative flow cytometry plots show the gating of monocytes within the blood of control-and ABX-treated rats. D, Circulating CD43 low and CD43 high monocytes were quantified in the blood of ABX-or controltreated WT and B27-Tg rats. E, Representative dot plots show the BM monocyte populations in control-or ABX-treated B27-Tg rats. F, CD43 low and CD43 high monocyte subsets were quantified in the BM of control-or ABX-treated WT and B27-Tg rats. In D and F, the numbers were calculated from 3 different experiments pooled together using B27-Tg rats (n 5 9 control-treated and n 5 12 ABX-treated) and from 1 experiment using WT rats (n 5 3 per treatment group). Symbols represent individual rats; horizontal bars indicate the mean. Data were analyzed using the Kruskal-Wallis test with Dunn's post hoc test in B and one-way analysis of variance with Sidak's multiple comparison test in D and F. * 5 P # 0.05; ** 5 P # 0.005; *** 5 P # 0.0005. See Figure 1 for other definitions.
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ANSALONE ET AL Figure 3 . Reduction in plasma CCL2 levels following antibiotic (ABX) treatment in B27-Tg rats. A, Representative histograms show uptake of CCL2 (CCL2 AF647 fluorescence) by CD43 low and CD43 high monocytes from the blood and BM of WT rats. Blood and BM cells were collected from WT rats and incubated with CCL2 AF647 , followed by staining for surface marker expression and flow cytometry analysis. The experiment used 3 different animals, each of which showed comparable results. B, Migration of CD43 high and CD43 low monocytes toward the CCL2 gradient was analyzed in the BM of WT rats. Total BM cells were placed in the top section of a bare-filter Transwell, and increasing concentrations of recombinant rat CCL2 were used as a chemoattractant in the bottom section of the Transwells. After 3 hours, transmigrated cells were collected, stained, and quantified by flow cytometry. Data were analyzed using two-way analysis of variance with Dunnett's post hoc test, comparing each concentration of CCL2 to the values at 0 ng/ml. Results are the mean 6 SD from 1 experiment performed in triplicate. C, Plasma was collected from B7-Tg control rats and B27-Tg rats, and plasma CCL2 levels were quantified by enzyme-linked immunosorbent assay (ELISA). Data were analyzed with the Mann-Whitney test. Symbols represent individual rats; horizontal bars indicate the mean. D, Blood from B27-Tg animals receiving the vehicle control (CTRL) was collected twice per week for 4 weeks, and the numbers of CD43 low monocytes and plasma CCL2 levels were measured in each sample. The samples were collected from 2 different experiments, and results were pooled (n 5 50). Correlation analysis was performed using Pearson's r test. E, Plasma was collected at different time points (days 1-26) from B27-Tg and WT rats treated with ABX or water as a vehicle control, and CCL2 levels were measured by ELISA. Plasma CCL2 levels were determined from 3 different experiments pooled together using B27-Tg rats, and from 1 experiment using WT rats. Results are the mean 6 SD (in B27-Tg rats, n 5 9 control-treated and n 5 12 ABX-treated; in WT rats, n 5 3 per treatment group). Data were analyzed using two-way analysis of variance and Sidak's multiple comparison test for repeated measures. F, Levels of interleukin-1a (IL-1a) were measured on day 21 in plasma samples from control-and ABX-treated WT and B27-Tg rats. Results are the mean 6 SD of 9-10 B27-Tg rats and 3 WT rats. Data were analyzed using the Kruskal-Wallis test with Dunn's multiple comparisons test. * 5 P # 0.05; ** 5 P # 0.005 (in E) or P # 0.01 (in F); *** 5 P # 0.0005; **** 5 P # 0.0001. See Figure 1 for other definitions.
GUT-BONE AXIS IN HLA-B27-Tg RATSa significant positive correlation between plasma CCL2 levels and the number of circulating CD43 low monocytes in B27-Tg rats ( Figure 3D ). Moreover, administration of antibiotics to B27-Tg rats significantly decreased the plasma levels of CCL2 ( Figure 3E ). Remarkably, 1 week after the initiation of antibiotics, the plasma CCL2 levels in B27-Tg rats returned to levels similar to those in WT controls ( Figure 3E) .
Furthermore, we evaluated whether the antibiotic treatment could affect the levels of systemic cytokines in B27-Tg rats. TNF is known to be highly linked to B27-associated disease; however, in this study, it was undetectable in both the plasma and serum of rats (data not shown). In contrast, the level of IL-1a (a potent proinflammatory cytokine often associated with TNF activity) was significantly higher in the plasma of B27-Tg rats compared to controls. Notably, the plasma IL-1a levels in B27-Tg rats substantially decreased following antibiotic treatment ( Figure 3F ). These data indicate that oral antibiotics not only reduce local inflammation in the gut but also have an impact on systemic inflammation by reducing the circulating levels of IL-1a, CCL2, and CD43 low monocytes. Effect of oral antibiotic treatment in reestablishing normal responsiveness to TNF within the BM preosteoclast compartment of B27-Tg rats. Recent studies have shown that murine monocyte subpopulations have differing osteoclastogenic potential (13) . Evaluation of the osteoclastogenic potential of each of the rat BM monocyte populations revealed that the CD43 low monocyte population contained the main osteoclast precursors (Figures 4A  and B) . Therefore, the observed increase in the CD43 low monocyte population in B27-Tg rats could contribute to the overt bone pathology observed in these animals as they age. Figure 4 . The highest number of osteoclasts were derived from CD43 low monocytes in vitro. BM cells (BMCs) were collected from WT, B7-Tg, and B27-Tg rats and specific monocyte populations were sorted using flow cytometry. The sorted cells were cultured at the same density in pro-osteoclastogenic medium (50 ng/ml macrophage colonystimulating factor and 50 ng/ml RANKL), and after 7 days, the cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP). A, Representative images show TRAP staining of total BMCs (stained with purple) in the different cell subpopulations analyzed. B, TRAP1 multinucleated cells (MNCs; $3 nuclei) were quantified as osteoclasts. Results are the mean 6 SD of 3 rats per group, from 3 different experiments pooled together. See Figure 1 for other definitions. Figure 5 . Reversal of the BM monocyte/osteoclast phenotype by antibiotic (ABX) treatment in B27-Tg animals. WT and B27-Tg rats received 4 weeks of ABX treatment or water as a vehicle control (CTRL), and on day 26, nonadherent BM cells were collected and cultured in the presence of 50 ng/ml macrophage colony-stimulating factor, 10 ng/ml RANKL, and 50 ng/ml tumor necrosis factor in triplicate wells. On day 4, the medium was refreshed, and on day 5, cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP). Osteoclasts were quantified as TRAP1 multinucleated cells (MNCs; $3 nuclei) from 4 digital images per well. A, The number of TRAP1 MNCs was determined in cultures of cells from control-or ABX-treated WT and B27-Tg animals. Data were derived from 2 different experiments pooled together (n 5 7-8 B27-Tg rats and n 5 3 WT rats). Symbols represent individual rats; horizontal bars indicate the mean. Data were analyzed with one-way analysis of variance and Sidak's multiple comparison test. * 5 P # 0.05; ** 5 P # 0.005. B, Representative images show TRAP staining of cultures from a control-treated and an ABX-treated B27-Tg rat. Original magnification 3 10. See Figure 1 for other definitions.
Furthermore, it has been demonstrated that BM precursors from B27-Tg rats undergo enhanced TNFdriven (but not RANKL-driven) osteoclastogenesis as compared to that in control rats (9) (for results, see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40154/abstract). Moreover, the enhancement of osteoclast differentiation by TNF in B27-Tg rats has been associated with both the production and activity of IL-1a (9), the levels of which were reduced in the plasma of B27-Tg animals upon treatment with oral antibiotics ( Figure  3F) . Importantly, the restoration of homeostasis within the monocyte compartment in B27-Tg rat BM after antibiotic treatment ( Figures 2E and F) also reversed the TNFdependent enhancement of osteoclast differentiation in these animals ( Figures 5A and B) . Thus, treatment of B27-Tg rats with oral antibiotics not only resolved their microbiota-dependent intestinal inflammation but also reduced the levels of circulating CCL2, restored homeostasis to blood and BM monocytes, and reversed the defects in generation of osteoclasts from these monocytes.
DISCUSSION
It is becoming increasingly apparent that the microbial environment within the gut is relevant not only to pathologic conditions in the intestine but also to the pathologic development of rheumatic diseases (e.g., rheumatoid arthritis and ankylosing spondylitis) (14) . Overexpression of HLA-B27 and b 2 -microglobulin in rats leads to a multisystem SpA-like inflammation that starts within the gut (1) and is associated with intestinal dysbiosis in the early stages of disease development (4, 15) . These animals provide a model to examine the mechanisms of the microbiotamediated systemic inflammation and bone disease that has been observed in HLA-B27-positive patients with axial SpA, who are often reported to have subclinical intestinal inflammation (16) .
Intestinal inflammation in B27-Tg animals leads to increased systemic levels of CCL2, and this is associated with higher numbers of CCR21CD43 low monocytes in both the BM and peripheral blood. The CCL2-CCR2 interaction is known to regulate monocyte release from the BM (where they are generated) into the bloodstream (17) . Perturbation of the activities of both CCL2 and CCR2 has been associated with impaired emigration of BM monocytes into the bloodstream, thus leading to lower numbers of circulating classical CCR21 monocytes in the steady state and during inflammation (18, 19) .
How peripheral inflammation can lead to increased CCL2 production and monocyte recruitment is still under debate. However, it is known that low concentrations of Toll-like receptor ligands in the blood induce CCL2 production within the BM, and this corresponds to an enhanced migration of CCR21 monocytes into the bloodstream (20) . Thus, an increase in the amounts of microbial molecules absorbed across the intestinal barrier might contribute to the initiation and progression of inflammatory responses. We therefore hypothesized that intestinal inflammation in B27-Tg rats can facilitate the dysregulation of the monocyte compartment by inducing increased CCL2 expression during the development and perpetuation of disease. This was supported by the fact that antibiotic treatment not only reduced the intestinal inflammation in B27-Tg rats but also normalized the levels of CCL2 and frequency of monocytes.
Interestingly, classical monocytes are generated within the BM and, when released into the bloodstream, they represent an obligatory intermediate state for the differentiation of "patrolling" monocytes (11, 21) . We observed a disconnect in this normal process in B27-Tg rats, which had higher levels of classical CD43 low monocytes that persisted in both the central compartment (BM) and peripheral compartment. The observed changes in monocytes in B27-Tg rats have important implications for bone disease, as we have demonstrated that CD43 low monocytes are the major precursors for osteoclasts in rats.
Furthermore, our data are consistent with the recent observation that BM cells from B27-Tg rats have pronounced increased osteoclastogenic potential only in the presence of TNF (9) . These data, taken together, may indicate that the B27-osteoclast phenotype directly results from an increase in the frequency of the CD43 low monocytes in B27-Tg animals. This interpretation is supported by the fact that antibiotic treatment reduced the severity of intestinal inflammation, systemic levels of CCL2, and numbers of BMderived and circulating CD43 low monocytes, and also reversed B27-associated TNF-enhanced osteoclastogenesis. Interestingly, previous studies have shown that anti-TNF treatment can inhibit both intestinal inflammation and enthesitis in the peripheral joints of B27-Tg animals (22) . However, the impact on CD43 low monocytes was not evaluated. It would therefore be interesting to determine whether anti-TNF treatment recapitulates those changes seen with antibiotic treatment.
One limitation of our study is that we were not able to show the in vivo consequences of antibiotic treatment on bone pathology. However, it is important to note that the B27-Tg rats used in this study were not old enough to show overt signs of bone disease. This includes no observable changes in circulating bone turnover markers (i.e., Cterminal crosslinking telopeptide of type I collagen and Nterminal type I procollagen propeptide) as well as no changes in osteoclast numbers at the bone surfaces or in bone architecture (as determined via micro-computed tomography) (data not shown). Studies in our laboratory have only been able to detect increased osteoclast numbers at bone surfaces and changes in bone architecture in B27-Tg rats that are a minimum of age 36 weeks (data not shown). Thus, further studies are required to evaluate the long-term impact of antibiotic treatment on bone pathology in this model.
In terms of human disease, alteration in the peripheral monocyte pool has also been found in patients with axial SpA. These patients have higher frequencies of classical CD14 high CD162 monocytes, a characteristic that corresponds to the increased frequency of CD43 low monocytes in the rat. This higher frequency of classical monocytes has been associated with spontaneous and elevated production of proinflammatory cytokines in patients with axial SpA during administration of conventional therapy but not during treatment with anti-TNF biologic agents, and this higher frequency also correlated with the Bath Ankylosing Spondylitis Disease Activity Index (23) . Taken together, these data support a direct and important role of classical monocytes in disease progression. However, further studies are still needed to assess the interaction between gut inflammation, the myeloid compartment, and the resulting clinical disease.
Recent studies have also started to address dysbiosis in rheumatic diseases, revealing alterations in the intestinal microbiome in patients with early rheumatoid arthritis (24, 25) , patients with axial SpA (26, 27) , and patients with psoriatic arthritis (PsA) (28) . However, once again, more work is required to understand the impact of intestinal perturbation on systemic pathology in remote sites such as the joints and bone. Notably, recent studies have shown that gut dysbiosis in patients with PsA correlates with a lower concentration of medium-chain fatty acids (MCFAs) and RANKL (28) . In the intestinal lumen, MCFAs have protective effects in maintaining the mucosal integrity, while RANKL promotes the differentiation of osteoclasts as well as dendritic cells. These findings support the concept that there is a potential link between gut dysbiosis/inflammation and the osteoclast compartment in PsA.
In conclusion, we have shown that modulation of the intestinal microbiota in an animal model of axial SpA has wide-ranging effects not only on systemic inflammatory cells and soluble mediators but also on osteoclastogenesis. This raises the possibility that manipulation of the intestinal microbiota in patients with axial SpA may provide clinical benefits by restoring homeostasis to both the immune system and the skeletal system.
